Department of Public Health, University of Cagliari, Cagliari, Italy.
J Affect Disord. 2012 Feb;136(3):775-80. doi: 10.1016/j.jad.2011.09.041. Epub 2011 Oct 24.
The prevalence of bipolar spectrum disorders in the community is under debate and the prescription of antidepressant drugs (ADs) in bipolar depression appears to be an underestimated problem.
To evaluate the prevalence of bipolar disorders by means of a screening instrument in seven communities within six regions of Italy and evaluate the appropriateness and number of prescriptions for ADs in bipolar depression.
community survey.
samples randomly drawn, after stratification from the adult population of municipal records.
4999 people from seven communities within six regions of Italy. Tools: questionnaire on psychotropic drug consumption, prescription, health services utilization; Structured Clinical Interview NP for DSM-IV modified (ANTAS); Mood Disorder Questionnaire (MDQ). Training: interviewers were trained psychologists or medical doctors.
the population studied did not represent a nationally representative multistage clustered area probability sample of households.
3398 subjects were interviewed (68% of recruited sample). Positivity at MDQ (MDQ+) was higher in males (3.4% vs. 2.8%) but the difference was not significant (OR=1.2, P=0.37). The association between MDQ+ and Major Depressive Disorder (MDD) was statistically significant for both males (OR=14.9, P<0.0001) and females (OR=8.3, P<0.001); 30% of subjects with MDQ+ and MDD lifetime diagnosis were taking ADs.
These overall rates of being MDQ+ are similar to community surveys conducted within USA and the use of ADs in people with MDQ+ and MDD diagnoses are.
社区中双相谱系障碍的患病率存在争议,双相抑郁患者中抗抑郁药(AD)的处方似乎是一个被低估的问题。
使用筛选工具评估意大利六个地区七个社区的双相障碍患病率,并评估双相抑郁中 AD 的使用的适宜性和数量。
社区调查。
从市政记录中的成年人群中分层后随机抽取的样本。
来自意大利六个地区七个社区的 4999 人。工具:关于精神药物消费、处方、卫生服务利用的问卷;DSM-IV 修改版的结构临床访谈 NP(ANTAS);心境障碍问卷(MDQ)。培训:访谈者是经过培训的心理学家或医生。
所研究的人群没有代表全国代表性的多阶段聚类地区家庭概率抽样。
对 3398 名被试进行了访谈(招募样本的 68%)。MDQ(MDQ+)阳性在男性中更高(3.4%对 2.8%),但差异无统计学意义(OR=1.2,P=0.37)。MDQ+与重性抑郁障碍(MDD)之间的关联在男性(OR=14.9,P<0.0001)和女性(OR=8.3,P<0.001)中均具有统计学意义;30%的 MDQ+和 MDD 终生诊断患者正在服用 AD。
这些 MDQ+的总体发生率与在美国进行的社区调查相似,在 MDQ+和 MDD 诊断患者中使用 AD 的情况也是如此。